4D Path
4D Path is dedicated to personalizing cancer care through advanced tumor response prediction technology. Their innovative QPOR™ platform directly measures and quantifies cell cycle deregulations and tumor microenvironment dynamics from routine biopsy images, enabling precise prediction of patient response to therapy. With a mission to democratize precision diagnostics, 4D Path aims to deliver faster, more accurate, and personalized cancer treatment solutions, improving patient outcomes worldwide.
Industries
Nr. of Employees
small (1-50)
Products
Digital image-to-report tumor profiling platform (patented treatment-prediction platform)
A cloud-based, end-to-end platform that analyzes digitized H&E whole-slide and cytology images to generate diagnostic outputs, quantitative biomarker indices, and treatment-response predictions without requiring additional molecular tests.
Digital image-to-report tumor profiling platform (patented treatment-prediction platform)
A cloud-based, end-to-end platform that analyzes digitized H&E whole-slide and cytology images to generate diagnostic outputs, quantitative biomarker indices, and treatment-response predictions without requiring additional molecular tests.
Services
Clinical validation collaborations and trial support
Designs and executes clinical validation studies and collaborates with academic and clinical partners to validate predictive biomarkers and platform performance in real-world and trial settings.
Integration and deployment into digital pathology workflows
Embeds image-analysis services into existing pathology viewers and PACS, provides format conversion, and supports scanner-agnostic deployment to fit established lab workflows.
Custom treatment-prediction signature development for therapeutics
Develops customized predictive signatures for specific therapies to support translational research and pharmaceutical development.
Automated histology stain quality assessment service
Provides automated image-based qualification of H&E staining protocols and quantitative adequacy metrics for laboratory quality control.
Regulatory support for image-based diagnostic submissions
Supports regulatory strategy and preparation for submissions of image-derived diagnostic adjuncts, informed by prior experience with Breakthrough Device designation.
Clinical validation collaborations and trial support
Designs and executes clinical validation studies and collaborates with academic and clinical partners to validate predictive biomarkers and platform performance in real-world and trial settings.
Integration and deployment into digital pathology workflows
Embeds image-analysis services into existing pathology viewers and PACS, provides format conversion, and supports scanner-agnostic deployment to fit established lab workflows.
Custom treatment-prediction signature development for therapeutics
Develops customized predictive signatures for specific therapies to support translational research and pharmaceutical development.
Automated histology stain quality assessment service
Provides automated image-based qualification of H&E staining protocols and quantitative adequacy metrics for laboratory quality control.
Regulatory support for image-based diagnostic submissions
Supports regulatory strategy and preparation for submissions of image-derived diagnostic adjuncts, informed by prior experience with Breakthrough Device designation.
Expertise Areas
- Histopathology image analysis
- Computational biomarker development
- Digital pathology workflow integration
- Translational clinical validation
Key Technologies
- Whole-slide image (WSI) analysis
- Physics-informed computational modeling
- Quantitative image biomarker generation
- Cloud-native scalable compute